WorldCare will discuss adjudication malignancy events in non-oncology trials
Boston, MA, May 1, 2016 – WorldCare Clinical (WCC), one of the world’s leading imaging CROs focused on maximizing the precision and accuracy of independent endpoint assessments in clinical trials, today announced that WCC President, Richard Walovitch, PhD, will present "Key Data Elements and Definitions for Adjudicating Malignancy Events in Non-Oncology Trials" at the Endpoint Adjudication Conference in Philadelphia on May 5, 2016.
"Cancer in non-oncology trials is a rare event that is often not captured by sites in a uniform fashion thus resulting in regulatory reporting inconsistencies," stated Dr. Walovitch. "We have developed an integrated pathology and oncology adjudication paradigm that allows us to evaluate any potential malignancies."
Developing a specific cancer adjudication program for a small unknown number of events can be expensive. In order to address these concerns, WCC has developed an "On-Demand" adjudication service which is structured so that sponsors are charged on a per-event bases. The adjudication service can also be scaled for large programs and currently adjudicates thousands of events a year from over 50 protocols and 1600 sites. All adjudications are performed by board certified Harvard pathologists and oncologists. In addition, WCC has access to whole slide digitization, tissue preparation and staining.
In order to maximize the precision and accuracy of data interpretation, WCC uniformly trains the subspecialty-trained, board-certified experts who perform all of WCC’s adjudication assessments. For more than 20 years, WCC has managed endpoint assessment committees, including adjudication of both imaging and non-imaging endpoints. WCC offers multiple standing safety committees as well as efficacy adjudication for all clinical subspecialties.
For more information on WCC's services, please visit our website at wcclinical.com or contact: